growth%20hormone%20deficiency
GROWTH HORMONE DEFICIENCY
Growth hormone deficiency in adults reflects an absence of two hormones, growth hormone and insulin-like growth factor-1 (IGF-1), affecting the process of glucose-insulin metabolism, lipolysis and bone remodelling.
History may show pituitary adenoma, surgery &/or radiation treatment of pituitary adenomas or cranial radiation for other disorders, deficiency of other pituitary hormones that may occur concurrently with growth hormone deficiency, and previous childhood growth hormone deficiency.
Physical exam reveals reduced lean body mass with increased weight, body fat predominantly in the abdominal region, thin & dry skin, cool peripheries, poor venous access and blunt affect.

Follow Up

Adults

  • Monitor monthly initially for response to treatment & adjust dose accordingly
  • Plasma glucose should be checked initially & every 3 months
  • Once maintenance doses are achieved, measurement of serum fasting blood sugar (FBS), insulin-like growth factor 1 (IGF-1), hemoglobin A1c (HbA1c), waist circumference, body mass index (BMI), serum free T4, & clinical assessment of hypothalamic-pituitary-adrenal axis or by early morning cortisol or cosyntropin stimulation test (in patients not on glucocorticoid replacement), testosterone, & fasting lipid panel should be done every 6-12 months
  • DEXA (Dual Energy X-ray Absorptiometry) scan is recommended prior to & during growth hormone (GH) therapy
    • 1st DEXA scan after initiation of GH replacement should be done at approx 2 years later & repeated at 2-3 year intervals

Children

  • Monitor every 3-6 months for response to treatment & adjust dose accordingly
  • Monitor thyroid function every 6 months
  • Continue GH therapy if there is persistent growth hormone deficiency (GHD) even after adult height is achieved to obtain full skeletal/muscle maturation during the transition period
  • GHD may persist to adult life
    • Retesting may be required esp in idiopathic GHD patients (retest using adult criteria after 1-3 months w/o GH therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tee Hoi Poh, 26 Sep 2018
Stool-based colorectal cancer (CRC) screening should be the preferred method of CRC screening in Malaysia, according to Dato Dr Muhammad Radzi Abu Hassan, the Head of Gastroenterology Services in Ministry of Health, Malaysia, who presented the Malaysian experience on CRC screening at the Annual Scientific Meeting of the Society of Gastroenterology and Hepatology (GUT) 2018 held recently in Penang.
Jackey Suen, 26 Nov 2018

Linagliptin has no impact on cognitive decline when given on top of standard of care in patients with type 2 diabetes mellitus (T2DM), a CARMELINA substudy has shown.